Sam Brown Healthcare Communications company information, Employees & Contact Information

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025 Sahm

Michael Heinley Joins Sam Brown Healthcare Communications As Managing Director, Client Development and Engagement Business Wire

Endeavor BioMedicines to Present Results from Phase 2a Trial of Taladegib (ENV-101) in an ALERT Session at European Respiratory Society (ERS) Congress 2025 Business Wire

Retired Army Capt. Sam Brown mounts 2nd bid for US Senate in Nevada after losing GOP primary in 2022 AP News

The Prostate Cancer Foundation and Society of Nuclear Medicine and Molecular Imaging (SNMMI) Collaborate to Advance Prostate Cancer Research Business Wire

Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference GlobeNewswire

ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results GlobeNewswire

MiNA Therapeutics Presents New Pre-Clinical Data from Sickle Cell Disease Program at the European Hematology Association 2025 Congress Business Wire

Prostate Cancer Foundation Provides Over $16 Million to Fund Innovative Prostate Cancer Research Through Annual Challenge Awards Program Business Wire

Endeavor BioMedicines Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference Business Wire

The Prostate Cancer Foundation Debuts Refreshed Website, Creating Enhanced Resource for Patients, Physicians, Researchers, Caregivers and Donors Business Wire

Endeavor BioMedicines Appoints Internationally Renowned ILD Expert Lisa Lancaster, M.D., as Chief Medical Officer Business Wire

MiNA Therapeutics Appoints Norbert Bischofberger, Ph.D., to its Board as Non-Executive Director and Bríd Ryan, Ph.D., MPH, as Chief Scientific Officer Business Wire

The Prostate Cancer Foundation Awards More Than $6 Million to Promising Young Investigators to Advance Prostate Cancer Research Business Wire

Sunbird Bio Appoints Vijay Parthasarathy, Ph.D., MBA, as Chief Product and Strategy Officer Business Wire

XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease Business Wire

Vergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgery Business Wire

Blue Matter Acquires Sam Brown Inc., a Leading Healthcare Corporate Communications and Public Relations Agency Business Wire

Tris Pharma Announces Acceptance of New Review Article Highlighting Challenges of Treating Moderate-to-Severe Acute Pain with Currently Available Drugs Business Wire

Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain Business Wire

Prostate Cancer Foundation Commences 30th Season of Annual Home Run Challenge Business Wire

Arcellx to Participate in Two Upcoming Investor Conferences Business Wire

Tris Pharma to Unveil Positive Phase 3 Results including a Strong Safety Profile Showcasing the Potential of Cebranopadol, an Investigational First-in-Class Dual-NMR Agonist for the Treatment of Pain, at the 2025 ASRA Annual Meeting Business Wire

Endeavor BioMedicines Receives Orphan Drug Designation from the U.S. Food and Drug Administration and European Commission for Taladegib (ENV-101) for the Treatment of Idiopathic Pulmonary Fibrosis Business Wire

First Patient Dosed in XyloCor Therapeutics’ Phase 2b EXACT-2 Trial Evaluating XC001 for the Treatment of Coronary Artery Disease Business Wire

Vergent Bioscience Presents Phase 2B VISUALIZE Results Demonstrating Abenacianine for Injection (VGT-309) with Intraoperative Molecular Imaging Improved Tumor Visualization During Lung Surgery Business Wire

Findings Presented at PAINWeek 2024 Demonstrate Tris Pharma’s Investigational, First-in-Class Therapy Cebranopadol Provides Potent, Prolonged Pain Relief with Improved Safety Over Oxycodone Business Wire

Blue Earth Diagnostics, a Bracco Company, Applauds New CMS Rule to Support Patient Access Through Improved Payment for Specialized Diagnostic Radiopharmaceuticals Business Wire

Blue Earth Diagnostics, a Bracco Company, Lauds CMS Proposal to Support Patient Access Through Improved Payment for Specialized Diagnostic Radiopharmaceuticals Business Wire

Vergent Bioscience Completes Enrollment in Phase 2 VISUALIZE Trial Evaluating Potential of Abenacianine for Injection (VGT-309) to Improve Tumor Visualization During Cancer Surgery Business Wire

Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer to Lead Company’s Next Phase of Business Growth Business Wire

Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD Business Wire

Arcellx Provides First Quarter 2024 Financial Results Business Wire

Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies Business Wire

Sunbird Bio to Present Data from Study Evaluating Tau Blood-Based Biomarkers at the Alzheimer’s Association International Conference® 2024 (AAIC®) Business Wire

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors Business Wire

MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases Business Wire

Blue Earth Therapeutics Highlights Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting Business Wire

Photo of Biohaven Pharmaceuticals Ringing the Opening Bell Available on Business Wire's Website and the Associated Press Photo Network Business Wire

Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder Business Wire

Tris Pharma Initiates ALLEVIATE-1 and ALLEVIATE-2, Pivotal Phase 3 Trials Investigating Cebranopadol, a First-in-Class Compound with a Novel Mechanism of Action to Treat Pain Business Wire

Blackstone Life Sciences Launches Uniquity Bio to Develop Novel Medicines in Immunology & Inflammation Business Wire

Blue Earth Therapeutics Announces Clinical Research Collaboration with UCL to Develop Innovative Alpha-labelled Radioligand Therapy (RLT) for Prostate Cancer Business Wire

Tris Pharma’s Once-Daily ADHD Medication, ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, Now Available in the United States Business Wire

First Patient Dosed in Endeavor BioMedicines’ Phase 2b WHISTLE-PF Trial Evaluating ENV-101 for the Treatment of Idiopathic Pulmonary Fibrosis Business Wire

Blue Earth Therapeutics Ltd Announces Expansion of Partnership With Seibersdorf Labor GmbH to Include Manufacture of Therapeutic Radiopharmaceutical, 225Ac-rhPSMA-10.1 Business Wire

Veradermics Raises $75 Million in Series B Financing and Initiates Phase 2/3 Trial for Hair Loss Business Wire

Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma Business Wire

Prostate Cancer Foundation Honors Maha Hussain, MD, FACP, FASCO, Recipient of the First PCF Women in Science Lifetime Achievement Award FinancialContent

Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline Business Wire

NewBiologix Launches with $50M to Advance Novel Technology Platform for the Manufacturing of Gene and Cell Therapies Business Wire

SR One Closes Second Venture Fund at $600 Million Business Wire

MBrace Therapeutics Raises $85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates Business Wire

Vergent Bioscience to Present New Efficacy Results from Phase 2 Clinical Trial of VGT-309 at Annual Meeting of The Society of Thoracic Surgeons The AI Journal

Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular Diseases and Cancers Business Wire

Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics Business Wire

Sunbird Bio Merges with Glympse Bio to Accelerate Development of Proprietary Protein-Based Diagnostic Technologies Business Wire

Vergent Bioscience Secures $21.5 Million Series B Financing to Advance Clinical Development of Tumor-Targeted Fluorescent Imaging Agent VGT-309 Business Wire

Selexis Appoints Roland Hoffmann- Hecht, PhD, as Chief Business Officer Business Wire

Intrance Medical Systems Completes $17 Million Series A Financing and Appoints Ed Schutter to Board of Directors Business Wire

Expansion Therapeutics Names Sudhir Rao Senior Vice President of Business Development Business Wire

Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product Business Wire

Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial Business Wire

CrownBio Acquires OcellO B.V. to Expand Its Preclinical In Vitro Drug Development Service Offerings Business Wire

Intrance Medical Systems Establishes U.S. Operations and Names Patrick Shea Chief Executive Officer Business Wire

Expansion Therapeutics Announces Key Additions and Updates to Scientific Advisory Board Business Wire

Similis Bio Partners With Blau Farmaceutica to Co-Develop Four Biosimilar Programs Business Wire

Expansion Therapeutics Appoints Raymond Kelleher, M.D., Ph.D., to its Board of Directors Business Wire

Volastra Therapeutics Appoints Charles Hugh-Jones as Chief Executive Officer Business Wire

Expansion Therapeutics Raises $80 Million Series B Financing to Treat Neurodegenerative Diseases Business Wire

Nature Medicine Publishes Full Results from Axial Therapeutics’ Phase 1b/2a Clinical Trial in Autism Spectrum Disorder (ASD) Business Wire

Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference The Malaysian Reserve

Crown Bioscience Announces Expedited Access to Well-Established ATCC and NIH Cell Lines for Large-Scale Screening Panels FinancialContent

CrownBio Acquires OcellO B.V. to Expand Its Preclinical In Vitro Drug Development Service Offerings FinancialContent